What did @orlysgrrl actually say?
The clip is brief and decontextualized. @orlysgrrl says: "So do you not know that I have feelings or do you just not care that I have feelings?" That's the entirety of the transcript. Without the reply video from @michelle_motor_city that prompted this, we're reading tea leaves here. But the GLP-1 category tag and the emotional framing make the implied subject pretty clear: emotional blunting, mood changes, or interpersonal friction that users commonly attribute to semaglutide or tirzepatide.
This appears to be a personal expression of emotional distress, possibly related to how a relationship or support system has responded to the creator's GLP-1 experience. It is not a medical claim. It's a feeling. And feelings, it turns out, are actually a documented and underexplored dimension of GLP-1 pharmacology.
Does the science back this up?
Yes, partially, and more than the FDA's current labeling reflects. There is growing clinical interest in how GLP-1 receptor agonists affect mood, emotional processing, and interpersonal dynamics. A 2023 pharmacovigilance analysis published in eClinicalMedicine (Kose et al.) identified signals for depression and suicidal ideation in the FDA Adverse Event Reporting System for semaglutide users, though causality remains unestablished.
Separately, GLP-1 receptors are expressed in limbic brain regions including the amygdala and hippocampus, areas involved in emotional regulation. Animal studies from Kanoski et al. (2016, Neuropharmacology) showed that GLP-1 receptor activation in the brain influences reward processing and anxiety-like behavior. Human data are limited but emerging. What clinicians are seeing anecdotally, and what patients are posting about, is a flattening of emotional reactivity that some find distressing and others find stabilizing. The science does not yet explain which patients experience which outcome, or why.
What did they get wrong (or right)?
@orlysgrrl did not make a false medical claim, so there's nothing to correct on that front. What's worth naming, though, is the broader pattern this clip fits into: people on GLP-1 medications experiencing emotional shifts that their social circles don't recognize or take seriously.
That's real, and it's documented. Research on weight loss and identity disruption, including work by Pratt et al. (2023, Obesity), shows that rapid body composition changes can destabilize personal relationships and self-perception in ways that the prescribing encounter rarely addresses. The emotional experience of being on a GLP-1 drug is not just about nausea and injection schedules. It involves changes in how people relate to food, pleasure, reward, and sometimes to other people.
What's missing from this clip, not a criticism of the creator but a gap worth flagging, is any connection to whether GLP-1 pharmacology might be contributing to whatever emotional friction she's describing. That's a conversation worth having with a prescriber, not just a TikTok audience.
What should you actually know?
If you're on a GLP-1 medication and noticing mood changes, emotional blunting, or shifts in how you relate to the people around you, you're not imagining it and you're not alone. This is an underreported side effect category, and the research is still catching up to what patients have been saying for two years.
The FDA added a safety review for suicidality signals to semaglutide in 2023, though the agency's preliminary conclusion was that evidence did not confirm causality. That review is ongoing. Liraglutide has longer safety data and does not carry the same signal at comparable intensity, but all GLP-1 drugs share the same receptor mechanism in brain tissue.
If you are experiencing significant mood changes, talk to your prescriber before adjusting your dose or stopping the medication. Abrupt discontinuation of GLP-1 therapy has its own documented effects on appetite and weight rebound, and a prescriber needs to weigh those against mood symptoms case by case. This is not a reason to avoid these medications. It is a reason to take the full picture of your experience seriously and to expect your prescriber to do the same.